Life Sciences Tools and Services
Company Overview of Duke Clinical Research Institute
Duke Clinical Research Institute operates as an academic clinical research organization in the United States and internationally. It offers clinical trial services; and outcomes research and assessments, clinical database design and management, and medical education services. The company provides its services in areas, such as cardiology, endocrinology, hepatology/GI, and geriatrics; and hematology, immunology and inflammation medicine, infectious diseases, nephrology, neurosciences medicine, oncology, ophthalmology, otolaryngology, pediatrics, perioperative medicine, primary care, pulmonary medicine, transplant medicine, and women's health. The company also provides education/training servi...
2400 Pratt Street
Durham, NC 27705
Founded in 1969
Key Executives for Duke Clinical Research Institute
Co-Chief of Pediatric Cardiology Division and Director of Pediatrics Research
Chief of Quantitative Sciences Division and Associate Director
Chief Human Resources Officer
Director of Business Development and Contracts Management
Compensation as of Fiscal Year 2013.
Duke Clinical Research Institute Key Developments
ARCA biopharma, Inc. Enter into Clinical Research Agreement with Duke Clinical Research Institute
Nov 6 13
ARCA biopharma, Inc. (ARCA) entered into a Clinical Research Agreement with Duke University’s Duke Clinical Research Institute (DCRI), to serve as the coordinating center and principal investigator for GENETIC-AF (the Study), a planned Phase 2B/3 genetically-targeted, comparative effectiveness clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation in patients with heart failure. Under the agreement, the DCRI will coordinate GENETIC-AF with the approximately 50 clinical sites in the United States that are planned to participate in the Study (the Study Sites) and the physician investigators at the Study Sites. The DCRI will enter into an agreement with each Study Site, and will provide all materials needed by the Study Sites to conduct the Study, including Gencaro and the comparator drug. All data generated from GENETIC-AF will be owned by ARCA, with the DCRI retaining the right to use the data for its internal, non-commercial purposes. All inventions directly related to Gencaro or arising from the protocol of the Study will be owned by ARCA, with ARCA having the option to license any other inventions arising from the Study. The publication of any peer-reviewed manuscripts will be reviewed and be subject to approval by a publications committee, which will be overseen by the steering committee of GENETIC-AF. The DCRI’s obligation to conduct GENETIC-AF is subject to the approval of the DCRI Institutional Review Board. The term of the Agreement will continue for the duration of the Study. ARCA may terminate the Agreement upon 90 days notice for any reason. In addition, the Agreement may be terminated immediately if the FDA withdraws approval for the Study, if animal, human or toxicological test results support termination of the Study, if adverse events related to the drugs administered in the Study emerge that support immediate termination, if the principal investigator at the DCRI cannot continue in that role and a successor acceptable to ARCA is not available, or if a material event occurs that affects ARCA’s ability to finance the Study.
Benitec Selects the Duke Clinical Research Unit as Site for Hepatitis C Phase I/II Clinical Trial
Mar 21 13
Benitec Biopharma Limited announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is being developed as a potential 'one-shot-cure' for Hepatitis C (HCV).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|